Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2011

View Archived Issues

Ortho-McNeil-Janssen discloses new gamma-secretase modulators

Tempero Pharmaceuticals presents novel histone deacetylase 9 inhibitors

Apricus seeks approval in Latin America for topical erectile dysfunction drug

New lysophospholipid S1P1 receptor agonists claimed

Stiefel submits NDA for tazarotene foam

Johns Hopkins receives NIH funding for 5-year research project

Pseudotyped VLP-based vaccines show promise against hepatitis C

Sanofi discovers novel CaMK-II subunit delta inhibitors

CR-845 advances in new phase II trial in postoperative pain

Intercept Pharmaceuticals and Servier enter diabetes collaboration

FDA approves generic levetiracetam injection

Scientists to assess biomarkers in ProTECT trial participants

Arena Pharmaceuticals and Eisai report on lorcaserin carcinogenicity study

Meridian Bioscience launches new rapid test for CDI in Europe

Quidel molecular RT-PCR assay obtains CE mark approval

U.S. Department of Defense contracts Neuralstem to develop brain tumor therapy

Helsinn Therapeutics begins ROMANA 1 and 2 trials in NSCLC-related cachexia

MMV identifies new antimalarial aminopyridine derivatives

Stellar Biotech and Sigma-Aldrich collaborate for keyhole limpet hemocyanin

NanoViricides provides pipeline update and plans first IND submission

DelMar Pharmaceuticals receives Canada Industrial Research Assistance Program funding

New radioimmunotherapy enters phase I evaluation in HER2-positive intra-abdominal cancers

Histone deacetylase 6 inhibitor reverses symptoms of Charcot-Marie-Tooth disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...